RATIONAL FOR CONTINUING TERLIPRESSIN AFTER ENDOSCOPIC VARICEAL LIGATION IN ACUTE VARICEAL HAEMORRHAGE NEEDS FURTHER EVIDENCE: A PILOT STUDY.

Ram Chandra Poudel Deba Prasad Dhibar Navneet Sharma Navneet Sharma Sunil Taneja Ajay Prakash

Published in: Arquivos de gastroenterologia (2022)

The rational for continuing terlipressin after EVL is doubtful as it didn't have any benefit for the prevention of re-bleed or mortality; rather it increased the risk of adverse drug reactions and duration of hospital stay. Further randomized clinical trials are encouraged to generate more evidence in support or against continuing terlipressin after EVL.

Keyphrases

adverse drug
medical education
drug induced
liver failure
electronic health record
emergency department
healthcare
ultrasound guided
cardiovascular events
clinical trial
cardiovascular disease
intensive care unit
coronary artery disease
acute care
acute respiratory distress syndrome